tweenvest

Iambic Therapeutics, Inc. (NasdaqGS: IAM)

Health Care · Biotechnology · US

$13.10

-11.73% today · -30.7% 1Y

Public summary
A free snapshot of Iambic Therapeutics, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Iambic Therapeutics, Inc. (NasdaqGS: IAM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $620.95M and employs 171 people.

Over the last twelve months the share price has lost 30.7%, trading between 10.17 and 25.00.

Tweenvest scores Iambic Therapeutics, Inc. across four factors: quality 50/100, value 67/100. Its strongest factor is value.

IAM price history

Oct 16, 2026 · 23.81Weekly closes 10.17 – 23.81Nov 13, 2026 · 13.10

Key figures

Market cap
$620.95M
Revenue (TTM)
$18.25M
P/E
-12.97
EPS
-3.57
Dividend yield
—
Beta (5Y)
—
52-week high
$25.00
52-week low
$10.17
Avg volume (3M)
—
Shares outstanding
47.40M
Employees
171
Next earnings
—

About Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

ISIN
US45076A1016
Founded
2019
Listed since
Oct 15, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Immix Biopharma, Inc.NasdaqCM: IMMX$626.92M$7.48-4.59%
DBV Technologies S.A.ENXTPA: DBV$624.05M€1.80-3.69%
Bicara Therapeutics Inc.NasdaqGM: BCAX$622.71M$9.38-2.29%
Lepu Biopharma Co., Ltd.SEHK: 2157$620.99MHK$2.70-3.57%
Shenzhen Weiguang Biological Products Co., Ltd.SZSE: 002880$620.89MCN¥18.26-3.23%
Arbutus Biopharma CorporationNasdaqGS: ABUS$619.30M$4.04-1.22%
Crescent Biopharma, Inc.NasdaqCM: CBIO$605.64M$14.15-1.53%
Surrozen, Inc.NasdaqCM: SRZN$602.54M$31.61-0.19%

Browse every Biotechnology company →